{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:16:06Z","timestamp":1766049366449,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["archives-pmr.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Physical Medicine and Rehabilitation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.apmr.2020.03.025","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T11:42:03Z","timestamp":1591011723000},"page":"1485-1496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial"],"prefix":"10.1016","volume":"101","author":[{"given":"Junekyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ho","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Uk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deog Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Jong","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum Sun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Ghil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apmr.2020.03.025_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/PHM.0b013e31825f13a3","article-title":"Spasticity after stroke: an overview of prevalence, test instruments, and treatments","volume":"91","author":"Sommerfeld","year":"2012","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1191\/0269215502cr512oa","article-title":"Prevalence of spasticity post stroke","volume":"16","author":"Watkins","year":"2002","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib3","first-page":"1793","article-title":"Caregiver burden, productivity loss, and indirect costs associated with caring for patients with poststroke spasticity","volume":"10","author":"Ganapathy","year":"2015","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.apmr.2020.03.025_bib4","doi-asserted-by":"crossref","first-page":"8329306","DOI":"10.1155\/2019\/8329306","article-title":"Efficacy and safety of botulinum toxin type a for limb spasticity after stroke: a meta-analysis of randomized controlled trials","volume":"2019","author":"Sun","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apmr.2020.03.025_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.23736\/S1973-9087.16.04329-X","article-title":"Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis","volume":"53","author":"Dong","year":"2017","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.apmr.2020.03.025_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00702-007-0869-3","article-title":"Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity","volume":"115","author":"Rosales","year":"2008","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.apmr.2020.03.025_bib7","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.apmr.2020.03.025_bib8","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.apmr.2020.03.025_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/toxins8010004","article-title":"Efficacy and safety of a new botulinum toxin type a free of complexing proteins","volume":"8","author":"Oh","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.apmr.2020.03.025_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys Ther"},{"key":"10.1016\/j.apmr.2020.03.025_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Kanovsky","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.apmr.2020.03.025_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2015.07.028","article-title":"Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial","volume":"357","author":"Nam","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.apmr.2020.03.025_bib13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0269215516689331","article-title":"Safety and efficacy of letibotulinumtoxinA(BOTULAX\u00ae) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial","volume":"31","author":"Do","year":"2017","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1053\/apmr.2002.35474","article-title":"Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity","volume":"83","author":"Brashear","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib15","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.46.5.1306","article-title":"Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Simpson","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.apmr.2020.03.025_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa011892","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke","volume":"347","author":"Brashear","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apmr.2020.03.025_bib17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","article-title":"Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke","volume":"85","author":"Childers","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10072-005-0379-8","article-title":"Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens","volume":"26","author":"Slawek","year":"2005","journal-title":"Neurol Sci"},{"key":"10.1016\/j.apmr.2020.03.025_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2013.11.022","article-title":"Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study","volume":"337","author":"Jost","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.apmr.2020.03.025_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128633","article-title":"Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial","volume":"10","author":"Seo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apmr.2020.03.025_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jnnp.2008.159657","article-title":"Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study","volume":"80","author":"Simpson","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.apmr.2020.03.025_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.apmr.2011.10.026","article-title":"Further assessment to determine the additive effect of botulinum toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability","volume":"93","author":"Wolf","year":"2012","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.apmr.2009.02.026","article-title":"A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke","volume":"90","author":"Meythaler","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2020.03.025_bib24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.apmr.2012.12.006","article-title":"Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis","volume":"94","author":"Foley","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"year":"2012","series-title":"National clinical guideline for stroke. Vol 20083","key":"10.1016\/j.apmr.2020.03.025_bib25"},{"key":"10.1016\/j.apmr.2020.03.025_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3121\/cmr.2007.716","article-title":"Botulinum toxin in poststroke spasticity","volume":"5","author":"Ozcakir","year":"2007","journal-title":"Clin Med Res"}],"container-title":["Archives of Physical Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999320303099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999320303099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T07:05:34Z","timestamp":1757747134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003999320303099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0003999320303099"],"URL":"https:\/\/doi.org\/10.1016\/j.apmr.2020.03.025","relation":{},"ISSN":["0003-9993"],"issn-type":[{"type":"print","value":"0003-9993"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Archives of Physical Medicine and Rehabilitation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apmr.2020.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Congress of Rehabilitation Medicine","name":"copyright","label":"Copyright"}]}}